期刊:Klinische Padiatrie [Thieme Medical Publishers (Germany)] 日期:2016-11-15卷期号:228 (06/07)
标识
DOI:10.1055/s-0036-1593554
摘要
The complex interplay between histone deacetylases (HDACs) and histone acetyltransferases (HATs) plays a crucial role in the regulation of gene expression. By removing and adding acetyl groups to histone proteins, the affinity of histones and DNA is tightly regulated. As key players of epigenetic and posttranslational modification, HDACs therefore represent a promising therapeutic target in cancer harboring distinct epigenomes from normal cells. Consequently, HDAC inhibitors (HDACi) are increasingly evaluated in clinical trials, with four HDACi already approved by the FDA for treating lymphomas and multiple myelomas. In order to develop novel HDACi as therapeutics, an unique in-house library of more than 200 HDACi was synthesized. To evaluate the antitumor effects of these novel HDACi in primary brain tumor models in vitro , an optimal screening workflow had to be established. The aim was to develop a standardized high throughput pipeline allowing for efficient screening of hundreds of compounds, while generating highly reproducible and accurate results in large panels of cell lines. An optimized workflow was achieved by automated dispensing of cell lines and reagents using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and HDACi using the D300e Digital Dispenser (Tecan). On the one hand, the introduction of the Multidrop Combi Reagent Dispenser allowed us to upscale the assay format from 96-well to 384-well plates, while ensuring the accurate dispensing of both cell suspension and CellTiter Glo reagent for the cell viability readout. On the other hand, the D300e Digital Dispenser ensures precise and fully automated application of compounds directly into microtiter plates at nanoliter scale. Combined with additional modifications of the screening procedure, the overall throughput was remarkably increased saving time and consumables. Employing our optimized workflow, we screened a panel of cell lines (n = 35) derived from different brain tumor entities and normal control tissues. The HDACi were evaluated for their effect on tumor cell viability. Subsequently, corresponding dose response profiles and IC 50 values were generated using an in-house bioinformatics pipeline. In addition, commercially available and clinically used HDACi (e.g. Vorinostat, Romidepsin, Belinostat, Panobinostat) were included as positive controls in the library. In summary, by employing the D300e Digital Dispenser in combination with the Multidrop Combi Reagent Dispenser, and by optimizing the screening protocol, an advanced workflow for cell-based evaluation of HDACi was established. We used the newly developed pipeline to evaluate the HDACi in-house library for its activity in different brain tumor entities, thereby creating a unique and comprehensive data set to identify distinct HDACi universally effective in brain tumor cell lines or particularly active in specific entities. Moreover, the most promising inhibitors will be selected for further synthetic improvement approaches regarding their pharmacodynamic and pharmacokinetic properties to provide potential lead compounds for further evaluation and future epigenetic treatment of brain tumors.